|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | University of Chicago |
|---|---|
| Collaborator: |
Schering-Plough |
| Information provided by: | University of Chicago |
| ClinicalTrials.gov Identifier: | NCT00618332 |
Purpose
We hypothesize that those patients with purely seasonal allergic rhinitis will decongest better than those subjects with another cause contributing to their symptoms. These latter patients will not improve as well on an intranasal steroid as those who decongest well, potentially explaining the 60% response rate in prior studies.
| Condition | Intervention |
|---|---|
|
Seasonal Allergic Rhinitis |
Drug: mometasone furoate nasal spray Drug: placebo |
| Study Type: | Interventional |
| Study Design: | Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment |
| Official Title: | Does the Response to a Nasal Decongestant Test Predict the Outcome to Treatment of Seasonal Allergic Rhinitis With Nasonex? |
| Estimated Enrollment: | 40 |
| Study Start Date: | April 2008 |
| Estimated Study Completion Date: | July 2009 |
| Primary Completion Date: | July 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
1: Active Comparator
2 weeks of treatment
|
Drug: mometasone furoate nasal spray
2 puffs in each nostril once a day for 2 weeks
|
|
2: Placebo Comparator
2 weeks of treatment
|
Drug: placebo
2 puffs in each nostril once a day for 2 weeks
|
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Exclusion Criteria
Contacts and Locations| United States, Illinois | |
| University of Chicago | |
| Chicago, Illinois, United States, 60637 | |
| Principal Investigator: | Ro M Naclerio, MD | University of Chicago |
More Information
| Responsible Party: | University of Chicago ( Robert M Naclerio, MD ) |
| Study ID Numbers: | 15624B |
| Study First Received: | February 6, 2008 |
| Last Updated: | May 6, 2009 |
| ClinicalTrials.gov Identifier: | NCT00618332 History of Changes |
| Health Authority: | United States: Institutional Review Board |
|
Anti-Inflammatory Agents Respiratory System Agents Otorhinolaryngologic Diseases Immune System Diseases Mometasone furoate Rhinitis Anti-Allergic Agents Cardiovascular Agents Pharmacologic Actions Nose Diseases |
Nasal Decongestants Hypersensitivity Respiratory Tract Diseases Respiratory Tract Infections Therapeutic Uses Rhinitis, Allergic, Seasonal Hypersensitivity, Immediate Vasoconstrictor Agents Respiratory Hypersensitivity |